Momelotinib is an oral Janus kinase(JAK)1/2 and activin A receptor type 1(ACVR1)inhibitor approved by the FDAin September 2023 for the treatment of adult anemia patients with moderate or severe myelofibrosis(MF),including primary MF and secondary MF.This article reviewed the mechanism of action,pharmacokinetics,clinical efficacy and safety of momelotinib.
维普
万方数据